H-CORE also coordinates the acquisition and distribution of a broad variety of COVID-19 therapeutics to help reduce severe disease, hospitalizations, and deaths.
H-CORE’s approach to COVID-19 treatments is like filling a medicine cabinet—H-CORE does not rely on one type, or one brand, or one treatment. The federal government invested in and continues to distribute a variety of countermeasures including monoclonal antibodies, pre-exposure prevention therapies, and oral antivirals.
Today, H-CORE makes
therapeutic products available—at no cost—to state and territorial health departments, community health centers, and Federal Retail Pharmacy Partners across the country including thousands of
Test to Treat sites nationwide. Nearly 11 million therapeutic courses have been made available so far to partners.
3.7MMonoclonal Antibodies Courses Made Available
Courses Made Available
1.2MPre-Exposure Therapy Courses Made Available